Cargando…
Variation in Adherence Measures to Imatinib Therapy
PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studie...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223484/ https://www.ncbi.nlm.nih.gov/pubmed/30241224 http://dx.doi.org/10.1200/JGO.2016.007906 |
_version_ | 1783369414619430912 |
---|---|
author | Yanamandra, Uday Malhotra, Pankaj Sahu, K.K. Sushma, Yanamandra Saini, Neha Chauhan, Pooja Gill, Jasmeen Rikhi, Deepika Khadwal, Alka Prakash, Gaurav Lad, Deepesh Suri, Vikas Kumari, Savita Varma, Neelam Varma, Subhash |
author_facet | Yanamandra, Uday Malhotra, Pankaj Sahu, K.K. Sushma, Yanamandra Saini, Neha Chauhan, Pooja Gill, Jasmeen Rikhi, Deepika Khadwal, Alka Prakash, Gaurav Lad, Deepesh Suri, Vikas Kumari, Savita Varma, Neelam Varma, Subhash |
author_sort | Yanamandra, Uday |
collection | PubMed |
description | PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. PATIENTS AND METHODS: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. RESULTS: A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the χ(2) test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 (P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ(2) (1,220) = 135.45 (P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P = .012). CONCLUSION: This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level. |
format | Online Article Text |
id | pubmed-6223484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-62234842018-11-13 Variation in Adherence Measures to Imatinib Therapy Yanamandra, Uday Malhotra, Pankaj Sahu, K.K. Sushma, Yanamandra Saini, Neha Chauhan, Pooja Gill, Jasmeen Rikhi, Deepika Khadwal, Alka Prakash, Gaurav Lad, Deepesh Suri, Vikas Kumari, Savita Varma, Neelam Varma, Subhash J Glob Oncol ORIGINAL REPORTS PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. PATIENTS AND METHODS: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. RESULTS: A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the χ(2) test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 (P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ(2) (1,220) = 135.45 (P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P = .012). CONCLUSION: This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level. American Society of Clinical Oncology 2017-03-24 /pmc/articles/PMC6223484/ /pubmed/30241224 http://dx.doi.org/10.1200/JGO.2016.007906 Text en © 2017 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Yanamandra, Uday Malhotra, Pankaj Sahu, K.K. Sushma, Yanamandra Saini, Neha Chauhan, Pooja Gill, Jasmeen Rikhi, Deepika Khadwal, Alka Prakash, Gaurav Lad, Deepesh Suri, Vikas Kumari, Savita Varma, Neelam Varma, Subhash Variation in Adherence Measures to Imatinib Therapy |
title | Variation in Adherence Measures to Imatinib Therapy |
title_full | Variation in Adherence Measures to Imatinib Therapy |
title_fullStr | Variation in Adherence Measures to Imatinib Therapy |
title_full_unstemmed | Variation in Adherence Measures to Imatinib Therapy |
title_short | Variation in Adherence Measures to Imatinib Therapy |
title_sort | variation in adherence measures to imatinib therapy |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223484/ https://www.ncbi.nlm.nih.gov/pubmed/30241224 http://dx.doi.org/10.1200/JGO.2016.007906 |
work_keys_str_mv | AT yanamandrauday variationinadherencemeasurestoimatinibtherapy AT malhotrapankaj variationinadherencemeasurestoimatinibtherapy AT sahukk variationinadherencemeasurestoimatinibtherapy AT sushmayanamandra variationinadherencemeasurestoimatinibtherapy AT sainineha variationinadherencemeasurestoimatinibtherapy AT chauhanpooja variationinadherencemeasurestoimatinibtherapy AT gilljasmeen variationinadherencemeasurestoimatinibtherapy AT rikhideepika variationinadherencemeasurestoimatinibtherapy AT khadwalalka variationinadherencemeasurestoimatinibtherapy AT prakashgaurav variationinadherencemeasurestoimatinibtherapy AT laddeepesh variationinadherencemeasurestoimatinibtherapy AT surivikas variationinadherencemeasurestoimatinibtherapy AT kumarisavita variationinadherencemeasurestoimatinibtherapy AT varmaneelam variationinadherencemeasurestoimatinibtherapy AT varmasubhash variationinadherencemeasurestoimatinibtherapy |